Table 1.
Tissue sample overview used in the present study with alphaherpesvirus infection statea
| Subject | Gender | Age (yr)b | Tissue | Presence (+) or absence (−) of: |
|
|---|---|---|---|---|---|
| HSV-1 latency | VZV latency | ||||
| 1 | F | 52 | TG | + | + |
| 2 | M | 12 | TG | + | − |
| 3 | F | 85 | TG | + | ND |
| 4 | F | 71 | TG | + | + |
| 5 | M | 39 | TG | + | − |
| 6 | 5 wks | FG | − | − | |
| 7 | 5 wks | FG | − | − | |
| 8 | M | 56 | TG | + | + |
| 9 | M | 77 | TG | − | + |
| 10 | F | 80 | TG | + | + |
| 11 | M | 62 | TG | − | + |
| 12 | F | 61 | TG | + | − |
| 13 | M | 41 | TG | + | − |
| 14 | M | 78 | TG | + | + |
| 15 | M | 36 | TG | − | − |
| 16 | F | 32 | TG | − | + |
| 17 | M | 35 | TG | − | + |
| 18 | M | 34 | TG | + | + |
| 19 | F | 17 | TG | + | − |
| 20 | M | 29 | TG | − | − |
a
F, female; M, male; TG, trigeminal ganglia; FG, facial ganglia; ND, not done.
b
Expressed in years except as noted.